Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients

M LUINSTRA, Mark Naunton, N K PETERSON, L BEREZNICKI

    Research output: Contribution to journalArticle

    Abstract

    Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine clopidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals. Clopidogrel prescribing was examined and the indication for discharge on clopidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54% of patients from the Royal Darwin Hospital and 39% of patients from the Royal Hobart Hospital discharged on clopidogrel met PBS criteria. The main reason for noncompliance with the PBS was absence of a history of cardiovascular or cerebrovascular events while on low-dose aspirin and an absence of contraindications to aspirin at the time of clopidogrel prescribing. Conclusion: Although clopidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.
    Original languageEnglish
    Pages (from-to)265-268
    Number of pages4
    JournalJournal of Pharmacy Practice and Research
    Volume39
    Issue number4
    Publication statusPublished - 2009

    Fingerprint Dive into the research topics of 'Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients'. Together they form a unique fingerprint.

  • Cite this